SAR Studies Leading to the Identification of a Novel Series of Metallo-beta-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model.
Leiris, S., Coelho, A., Castandet, J., Bayet, M., Lozano, C., Bougnon, J., Bousquet, J., Everett, M., Lemonnier, M., Sprynski, N., Zalacain, M., Pallin, T.D., Cramp, M.C., Jennings, N., Raphy, G., Jones, M.W., Pattipati, R., Shankar, B., Sivasubrahmanyam, R., Soodhagani, A.K., Juventhala, R.R., Pottabathini, N., Pothukanuri, S., Benvenuti, M., Pozzi, C., Mangani, S., De Luca, F., Cerboni, G., Docquier, J.D., Davies, D.T.(2019) ACS Infect Dis 5: 131-140
- PubMed: 30427656 
- DOI: https://doi.org/10.1021/acsinfecdis.8b00246
- Primary Citation of Related Structures:  
5MXQ, 5MXR, 6HF5 - PubMed Abstract: 
The clinical effectiveness of carbapenem antibiotics such as meropenem is becoming increasingly compromised by the spread of both metallo-β-lactamase (MBL) and serine-β-lactamase (SBL) enzymes on mobile genetic elements, stimulating research to find new β-lactamase inhibitors to be used in conjunction with carbapenems and other β-lactam antibiotics. Herein, we describe our initial exploration of a novel chemical series of metallo-β-lactamase inhibitors, from concept to efficacy, in a survival model using an advanced tool compound (ANT431) in conjunction with meropenem.
Organizational Affiliation: 
Antabio SAS , 436 rue Pierre et Marie Curie , 31670 Labège , France.